l e t t e r s
To identify variants for multiple myeloma risk, we conducted a genome-wide association study with validation in additional series totaling 4,692 individuals with multiple myeloma (cases) and 10,990 controls. We identified four risk loci at 3q26.2 (rs10936599, P = 8.70 × 10 −14 ), 6p21.33 (rs2285803, PSORS1C2, P = 9.67 × 10 −11 ), 17p11.2 (rs4273077, TNFRSF13B, P = 7.67 × 10 −9 ) and 22q13.1 (rs877529, CBX7, P = 7.63 × 10 −16 ). These data provide further evidence for genetic susceptibility to this B-cell hematological malignancy, as well as insight into the biological basis of predisposition.
Multiple myeloma is a malignancy of plasma cells 1 . There are around 20,000 new cases of multiple myeloma in the United States each year, and just over half that number die of the disease each year 2 . We previously reported results of a genome-wide association study (GWAS) of multiple myeloma that was based on an analysis of UK and German series in which we identified risk loci at 2p23.3, 3p22.1 and 7p15.3 through fasttrack analysis of SNPs with the smallest P values 3 . We subsequently conducted further follow-up analyses using an expanded German GWAS and identified four new susceptibility loci for multiple myeloma.
After quality control, the previously reported German GWAS data set 4 comprised 1,014 cases recruited through Heidelberg University genotyped using Illumina OmniExpress BeadChips. We compared the genotype frequencies in these cases with genotype data generated by the Heinz-Nixdorf Recall (HNR) study of 2,107 individuals 5 from the German population who had been genotyped using Illumina Human Omni1-Quad BeadChips or Illumina OmniExpress BeadChips (Online Methods).
After quality control, the previously reported UK GWAS 3 comprised 1,321 cases recruited from the UK Medical Research Council (MRC) Myeloma IX trial 6 genotyped using Illumina OmniExpress BeadChips. We compared the genotype frequencies in these cases to publicly accessible genotype data generated by the UK Wellcome Trust Case Control Consortium 2 (WTCCC2) study of 2,698 individuals from the 1958 British Birth Cohort (known as 58C) 7 and 2,501 individuals from the UK Blood Service (UKBS) collections that had been genotyped using Illumina Human 1.2M-Duo Custom_v1 Array BeadChips (Online Methods).
Genotype data from the GWAS were filtered on the basis of prespecified quality-control measures (Online Methods). Individual SNPs were excluded from further analysis if they showed deviation from Hardy-Weinberg equilibrium with P < 1.0 × 10 −6 in controls, individual SNP genotype yield <95% or minor allele frequency (MAF) < 1%. After filtering, 414,804 autosomal SNPs common to both case-control series were analyzable (Online Methods, and Supplementary Figs. 1 and 2) .
Before undertaking a meta-analysis of the two GWAS, we searched for potential errors and biases in the data sets. Quantile-quantile plots of the genome-wide χ 2 values showed that there was minimal inflation of the test statistics, rendering substantial cryptic population substructure or differential genotype calling between cases and Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk 1 2 2 2 VOLUME 45 | NUMBER 10 | OCTOBER 2013 Nature GeNetics l e t t e r s controls unlikely in either GWAS (the genomic control inflation factor 8 (λ gc ) was 1.033 in the UK GWAS and 1.17 in the German GWAS; Supplementary Fig. 3 ). For completeness, we performed a principal components analysis using Eigenstrat 9 software to determine the effects of population substructure on our findings (λ corrected = 1.014 in the UK GWAS and λ corrected = 1.029 in the German GWAS; Supplementary Fig. 3) .
Using data on all cases and controls from both GWAS, we derived joint odds ratios (ORs) and confidence intervals (CIs) under a fixed-effects model for each SNP and the associated P values 10 . In the combined analysis, we identified nine SNPs showing good evidence of association (P < 5.0 × 10 −6 ) that mapped to distinct loci that have not previously been associated with multiple myeloma risk (Supplementary Table 1 ). The P value threshold used does not exclude the possibility that other SNPs represent genuine association signals, but it was a pragmatic strategy for prioritizing replication here.
To validate our findings, we conducted a replication study of the nine SNPs by genotyping samples from three additional series: UK replication 1, comprising 812 cases ascertained through the UK MRC Myeloma IX and XI trials and 1,110 controls; UK replication 2, comprising 396 cases collected through UK hematology centers and 992 controls; and the German replication, comprising 1,149 cases collected through the German Myeloma Study Group (DSMM), Heidelberg University Clinic and Ulm University Clinic and 1,582 regional controls (Online Methods). In the combined analysis, four SNPs, rs10936599 (3q26.2, P = 8.70 × 10 −14 ), rs2285803 (6p21.33, P = 9.67 × 10 −11 ), rs4273077 (17p11.2, P = 7.67 × 10 −9 ) and rs877529 (22q13.1, P = 7.63 × 10 −16 ), showed genome-wide significant evidence for an association with multiple myeloma ( Table 1, Online Methods  and Supplementary Table 2 ). rs10936599 at 3q26.2 (P = 8.70 × 10 −14 ; Table 1 ) is responsible for the H717H polymorphism in MYNN, the myoneurin gene (MIM606042). The rs10936599 G risk allele has also previously been shown to influence colorectal cancer risk 11 . Whereas MYNN encodes a zinc finger protein of unknown function that is expressed principally in muscle, rs10936599 (169,492,101 bp) maps within a 250-kb region of linkage disequilibrium (LD) that also encompasses TERC, the telomerase RNA component gene (MIM602322). Telomerase reactivation and telomerase-mediated elongation of shorter telomeres is a feature of multiple myeloma 12 . Because carrier status for the rs10936599 G risk allele is associated with significantly longer telomeres 12 , TERC is an attractive candidate for multiple myeloma susceptibility. Moreover, imputation of untyped genotypes in cases and controls using data from 1000 Genomes provided a marginally stronger association at 3q26.2 with the A allele of rs2293607, which maps 63 bp 5′ to TERC (P = 6.2 × 10 −10 compared with P = 1.3 × 10 −9 for rs10936599 in a meta-analysis of GWAS data; Fig. 1 ). The A allele of rs2293607 was recently shown to be associated with TERC mRNA expression and longer telomeres in vitro 12 , supporting variation in TERC as the basis of the 3q26.2 cancer association. npg l e t t e r s rs2285803 (P = 9.67 × 10 −11 ; Table 1 and Fig. 1 ) localizes in intron 5 of PSORS1C1, the putative psoriasis susceptibility gene(MIM613525) at 6p21.33 (31,107,245 bp). The 163-kb region of LD also encompasses CCHCR1 (MIM605310), CDSN (MIM602593), TCF19, the transcription factor 19 gene (MIM600912) and POU5F1, the POU domain, class 5, transcription factor 1 gene (MIM164177). Although there is currently no evidence for a role of POU5F1 in multiple myeloma, the gene encodes OCT3 (also known as OCT4), which regulates pluripotency, lineage commitment and tissue-specific gene expression. Variation at 6p21.33 has previously been shown to be associated with risk for follicular and Hodgkin's lymphomas. The associations for follicular lymphoma were defined by rs6457327 in the HLA class I region 13 and rs10484561 and rs2647012 in the HLA class II region 14, 15 . The Hodgkin's lymphoma association at 6p21.33 is marked by rs6903608 in the HLA class II region 16 . The multiple myeloma risk associated with each of these SNPs was nonsignificant (Supplementary Table 3) . To further investigate the rs2285803 signal for multiple myeloma, we imputed classical HLA alleles from SNP data from both GWAS using HLA*IMP 17, 18 . The strongest HLA association was provided by HLA-DRB5*01 (P = 1.42 × 10 −5 ; Supplementary Table 4), which was substantially weaker than that provided by rs2285803 (P = 3.07 × 10 −8 ). To evaluate the independence of the associations, we conducted regression jointly on rs2285803 and the imputed HLA alleles. Conditional analysis showed that most, but not all, of the MHC variation defined by SNP genotype could be explained by rs2285803 (Supplementary Table 4) . rs4273077 (P = 7.67 × 10 −9 ; Table 1 ) maps within intron 2 of TNFRSF13B, the gene for Homo sapiens tumor necrosis factor receptor superfamily member 13B (MIM604907) at 17p11.2 (16,849,139 bp; Fig. 1) . TNFRSF13B (also known as TACI) is a strong candidate for multiple myeloma predisposition a priori. TNFRSF13B is a key regulator of B-and T-cell function, as it is required for the development of transitional (T2) and mature B lymphocytes and the regulation of normal B-cell homeostasis 19 . Variation at TNFRSF13B influences circulating IgG concentrations 20 , and Tnfrsf13b −/− mice show an expanded B-cell population with lymphoproliferation and lymphoma risk 21 . As TNFRSF13B mutation is a risk factor for antibody-deficient (MIM240500) and selective immunoglobulin (Ig) deficiency (MIM609529) associated with lymphoproliferation, it is probable that loss of TNFRSF13B function impairs isotype switching. Primary multiple myeloma cells with high TNFRSF13B expression (TACI high ) resemble bone marrow plasma cells, which depend on interaction with the bone marrow environment. In contrast, multiple myeloma cells with low expression of TNFRSF13B (TACI low ) resemble plasmablasts 22 . TACI-Ig, a soluble receptor that blocks the TNFRSF13B ligands BAF and APRIL, inhibits the growth of TACI high but not TACI low myeloma cells in the severe combined immunodeficient mouse-human (SCID-hu) model 23 .
rs877529 localizes to intron 2 of CBX7, the chromobox homolog 7 gene (MIM608457) at 22q13.1 (39,542,292 bp; P = 7.63 × 10 −16 ; Table 1 and Fig. 1 ). CBX7 encodes a polycomb group protein; proteins from this group form part of a gene regulatory mechanism that determines cell fate during development and also contribute to the control of normal cell growth and differentiation 24 . CBX7-mediated repression of transcription acts through CDKN2A (also called INK4A or ARF) 25 , cooperating with MYC to promote aggressive B-cell lymphomagenesis, with high amounts of CBX7 being a feature of germinal center-derived follicular lymphoma 26 .
To explore whether any of the associations reflect cis-acting regulatory effects, we studied mRNA expression in CD138-selected plasma cells 27 and lymphoblastoid cell lines [28] [29] [30] (Online Methods and   Supplementary Table 5 ). Although we found no association between genotype and the expression of either mRNA transcript, steady-state levels of RNA at a single time point may not adequately capture the impact of differential expression in tumorigenesis. To explore the epigenetic profiles of the association signals, we used chromatin state segmentation in lymphoblastoid cell-line data generated by the ENCODE Project 31 . rs2293607 maps to a region of active chromatin that is predicted by the ENCODE data to be an active promoter, and rs877529 maps to within a strong enhancer element in CBX7 (Fig. 1) .
Hierarchically, multiple myeloma can be divided broadly into hyperdiploid and nonhyperdiploid subtypes 32, 33 . The latter is composed primarily of patients harboring IgH translocations, principally t(11;14)(q13;q32) and t(4;14)(p16;q32) 34, 35 . A case-only analysis provided no evidence for a subtype-specific association with genotype for rs10936599, rs2285803 or rs4237077, which is consistent with each variant having a generic effect on multiple myeloma risk (Supplementary Table 6 ). In contrast, rs877529 showed evidence that the association is driven by non-t(11;14) multiple myeloma, which remained significant after correction for multiple testing (P unadjusted = 8.0 × 10 −4 , P adjusted = 0.016).
Our findings provide further evidence for an inherited genetic susceptibility to multiple myeloma and insight into the development of this hematological malignancy. We estimate that the seven loci we have identified so far account for ~13% of the familial risk of multiple myeloma. Although the power of our study to detect the major common loci conferring risk ≥1.3 was high, we had low power to detect alleles with smaller effects and/or MAF < 0.1. By implication, variants with such profiles probably represent a much larger class of susceptibility loci for multiple myeloma because of the truly small effect sizes or submaximal LD with tagging SNPs. Thus, it is probable that a large number of variants remain to be discovered. This assertion is supported by the continued excess of associations observed over those expected, in addition to the regions studied here. Further efforts to expand the scale of GWAS, in terms of both sample size and SNP coverage, and increase the number of SNPs taken forward to large-scale replication may therefore identify additional risk variants. In addition, as we have recently shown, stratified analysis of multiple myeloma by karyotype may lead to the discovery of additional subtype-specific risk variants 4 . 
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Details of this study have been reported previously 3 . Briefly, 1,371 cases (ICD-10 C90.0; 469 male; mean age at diagnosis, 63.9 years; s.d., 9.9 years) were ascertained through the UK MRC Myeloma IX trial 6 . Genotyping of cases was performed using Illumina Human OmniExpress-12 v1.0 arrays according to the manufacturer's protocols (Illumina, San Diego, USA). For controls, we used publicly accessible data generated by WTCCC2 from the 1958 Birth Cohort (58C; also known as the National Child Development Study) 7 and the UKBS. Genotyping of controls was conducted using Illumina Human 1-2M-Duo Custon_v1 Array chips. SNP calling was performed using Illuminus Software. The full details of genotyping, SNP calling and quality control have been reported previously (http://www. wtccc.org.uk).
German GWAS. The German GWAS comprised 384 cases (229 male; mean age at diagnosis, 54.5 years; s.d., 8.0 years), which were the subject of a previous publication 3 , and an additional series of 698 cases (389 male; mean age at diagnosis, 59 years; s.d., 9.3 years) recruited by the German Multiple Myeloma Study Group (GMMG) coordinated by the University Clinic, Heidelberg. All cases were genotyped using Illumina Human OmniExpress-12 v1.0 arrays according to the manufacturer's protocols (Illumina, San Diego, USA). For controls, we used genotype data on 2,132 healthy individuals enrolled in the HNR study 5 ; of these controls, 704 were genotyped using Illumina HumanOmni1-Quad_v1 and 1,428 were genotyped using the OmniExpress-12 v1.0.
Quality control of GWAS data sets. DNA samples with GenCall scores <0.25 at any locus were considered to be 'no calls' . A SNP was deemed to have failed if <95% of the DNA samples generated a genotype at the locus. Cluster plots were manually inspected for all SNPs considered for replication. The same quality-control metrics on the new German GWAS data were applied as in our previous multiple myeloma study 3 . We restricted our analyses to samples in which >95% of SNPs were successfully genotyped, thus eliminating ten samples (Supplementary Fig. 1 ). We computed identity-by-state (IBS) probabilities for all pairs (cases and controls) to search for duplicates and closely related individuals among the samples (defined as IBS ≥ 0.80, thereby excluding first-degree relatives). For all identical pairs, the sample having the highest call rate was retained, eliminating 13 samples. To identify individuals who might have non-western European ancestry, we merged our case and control data with phase II HapMap samples (60 western European (CEU), 60 Nigerian (YRI), 90 Japanese (JPT) and 90 Han Chinese (CHB) samples). For each pair of individuals, we calculated genome-wide IBS distances on markers shared between HapMap and our SNP panel and used these as dissimilarity measures on which to perform principal components analysis. The first two principal components for each individual were plotted, and any individual not present in the main CEU cluster was excluded from analyses. We removed 70 samples of non-CEU ancestry (some of which had poor call rates). We filtered out SNPs having MAF <1% and call rate <95% in cases or controls. We also excluded SNPs showing departure from Hardy-Weinberg equilibrium at P < 10 −6 in controls. For replication and validation analyses, the call rates were >95% per 384-well plate for each SNP; cluster plots were visually examined by two researchers.
Replication series and genotyping. UK replication 1 comprised 812 cases (412 male) collected through the UK MRC Myeloma IX (n = 95) and XI trials (n = 717). Controls comprised 1,110 healthy individuals with self-reported European ancestry (420 male, aged 18-69 years) with no personal history of malignancy ascertained through the GELCAPS (n = 536) 36 and NSCCG (n = 574) 37 studies. All cases and controls were subjects of the UK.
UK replication 2 comprised 396 cases (181 male; mean age at diagnosis, 66.0 years; s.d., 12. Replication genotyping was performed using competitive allele-specific PCR KASPar chemistry (KBiosciences Ltd, Hertfordshire, UK). All primers and probes used are available on request. Samples having SNP call rates <90% were excluded from the analysis. To ensure the quality of genotyping in all assays, at least two negative controls and 1-2% duplicates (showing a concordance >99.99%) were genotyped. To exclude technical artifacts in genotyping, we performed cross-platform validation of 384 samples and sequenced a set of 384 randomly selected samples from each case and control series to confirm genotyping accuracy (concordance >99.9%).
Sample preparation. For German cases, DNA was prepared from ethylenediaminetetraacetic acid (EDTA)-venous blood samples, 100% of the original GWAS, 42% of the additional GWAS and 91% of the replication samples; for the remaining cases, the source was the CD138-negative fraction of bone marrow cells, with <5% contamination by tumor cells. For all UK cases, DNA was prepared from EDTA-venous blood samples. Samples were obtained before delivery of chemotherapy in the vast majority of UK cases and in at least 80% of the German cases. All DNAs were extracted using Qiagen FlexiGene or QIAamp methodologies and quantified using PicoGreen (Invitrogen).
Statistical and bioinformatic analyses. The main analyses were undertaken using R (v2.6), STATA v.10 (State College, Texas, US) and PLINK (v1.06) 38 software. ORs, 95% CIs and associated P values were calculated by unconditional logistic regression. The adequacy of the case-control matching and the possibility of differential genotyping of cases and controls were formally evaluated using quantile-quantile plots of test statistics. The inflation factor, λ, was based on the 90% least significant SNPs 8 . We undertook adjustment for possible population substructure using Eigenstrat software. The meta-analysis was conducted using standard methods 10 . Cochran's Q statistic to test for heterogeneity 10 and the I 2 statistic to quantify the proportion of the total variation due to heterogeneity were calculated 39 . I 2 values ≥75% are considered to be characteristic of large heterogeneity 39, 40 . To conduct a pooled analysis incorporating Eigenstrat-adjusted P values from the GWAS, we used the weighted Z-method implemented in the program METAL 41 . Because not all the HNR controls were genotyped using the same Illumina array, the robustness of the genome-wide associations was formally assessed by deriving ORs for the different German case-control combinations and incorporation of these data in the meta-analysis (Supplementary Fig. 4) . We examined each SNP for dose response by comparing 1-degree-of-freedom (1-d.f.) and 2-d.f. logistic regression models, adjusting for stage using a likelihood ratio test, and examined the combined effects of multiple SNPs by evaluating the effect of adding an interaction term to the model using a likelihood ratio test and adjusting for stage. Associations by tumor karyotype were examined by logistic regression in case-only analyses. The sibling relative risk attributable to a given SNP was calculated using the formula: where p is the population frequency of the minor allele, q = 1 − p, and r 1 and r 2 are the relative risks (estimated as ORs) for heterozygotes and rare homozygotes, respectively, relative to common homozygotes. Assuming a multiplicative interaction, the proportion of the familial risk attributable to a SNP was calculated as log λ*/logλ 0 , where λ 0 is the overall familial relative risk estimated from epidemiological studies, which was assumed to be 2. 45 (ref. 42) . Prediction of the untyped SNPs was carried out using IMPUTEv2 based on the 1000 Genomes phase 1 integrated variant set (b37) from March 2012. Imputed data were analyzed using SNPTEST v2 to account for uncertainties in SNP prediction, and the meta-analysis was performed using METAv1.4 (ref. 43 ).
npg LD metrics were calculated in PLINK using 1000 Genomes data and plotted using SNAP. LD blocks were defined on the basis of the HapMap recombination rate (cM/Mb) defined using the Oxford recombination hotspots 44 and on the basis of the distribution of CIs defined by Gabriel et al. 45 . We imputed classical HLA alleles from GWAS SNPs using HLA*IMP 17, 18 .
To explore the epigenetic profiles of the association signals, we used chromatin state segmentation in lymphoblastoid cell-line data generated by the ENCODE Project 31 . The states were inferred from ENCODE Histone Modification data (histone H4 Lys20 methylation (H4K20me1), histone H3 Lys9 acetylation (H3K9ac), H3K4me3, H3K4me2, H3K4me1, H3K36me3, H3K27me3, H3K27ac and CTCF) binarized using a multivariate hidden Markov model.
Karyotyping and FISH.
Conventional cytogenetic studies of multiple myeloma cells were conducted using standard karyotyping methodologies, and standard criteria for the definition of a clone were applied. FISH and ploidy classification of UK samples were conducted using the methodology described by Chiecchio et al. 46 . FISH and ploidy classification of German samples were performed as previously described 47 . The XL IGH Break Apart probe (MetaSystems, Altlussheim Germany) was used to detect any IgH translocation in German samples.
Relationship between SNP genotype and mRNA expression. To examine for a relationship between SNP genotype and mRNA expression in multiple myeloma, we used Affymetrix Human Genome U133+2.0 array data on the plasma cells from 192 patients with multiple myeloma from the MRC Myeloma IX trial 27 . To assay TERC, which was not captured on the U133+2.0 array, we used Affymetrix GeneChip miRNA 2.0 data. To examine for a relationship between SNP genotype and expression levels in lymphocytes, we used publicly available expression data generated on lymphoblastoid cell lines from HapMap3 (ref. 29) , Geneva GenCord individuals 30 and the MuTHER resource 28 using Sentrix Human-6 Expression BeadChips (Illumina, San Diego, USA) 48, 49 .
